Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies, has recieved a $1.5 million milestone payment from Lummy Co. Ltd. of Hong Kong. 

The milestone payment was made in consideration of the successful initiation of technology transfer related to the manufacturing of Rocapuldencel-T to Lummy by the Company, to which Lummy has a license for commercialization in these territories. 

“We appreciate Lummy’s continued commitment to Argos and the Rocapuldencel-T development program,” stated Jeff Abbey, chief executive officer of Argos. “Given the complexity of the manufacturing process for Rocapuldencel-T, we were pleased to complete this important milestone in our alliance.”